HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · IEX Real-Time Price · USD
1.530
-0.130 (-7.83%)
Apr 19, 2024, 4:30 PM EDT - Market closed
HCW Biologics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for HCW Biologics stock has a target of 9.00, which predicts an increase of 488.24% from the current stock price of 1.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 1, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for HCW Biologics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| EF Hutton | EF Hutton | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +488.24% | Jun 1, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +488.24% | Apr 19, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +488.24% | Mar 30, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +488.24% | Mar 23, 2023 |
| JonesTrading | JonesTrading | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +422.88% | Nov 8, 2022 |
Financial Forecast
Revenue This Year
1.33M
from 560.36K
Increased by 136.63%
Revenue Next Year
816.00K
from 1.33M
Decreased by -38.46%
EPS This Year
-0.58
from -0.70
EPS Next Year
-0.58
from -0.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.7M | 1.7M | 945,000 | 56.0M | 168.5M |
| Avg | 1.3M | 816,000 | 459,000 | 54.4M | 163.7M |
| Low | n/a | n/a | n/a | 52.3M | 157.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 387.2% | 26.7% | 15.8% | 12,106.5% | 209.6% |
| Avg | 136.6% | -38.5% | -43.8% | 11,757.7% | 200.8% |
| Low | - | - | - | 11,292.8% | 189.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.60 | -0.58 | -0.66 |
| Avg | -0.58 | -0.58 | -0.66 |
| Low | -0.56 | -0.58 | -0.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.